Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab plus chemotherapy in ES-SCLC
NCT05116007Phase 1Completed
- Sponsor
- Akeso, Inc.
- Start
- Mar 2021
- Primary completion
- Dec 2023
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ivonescimab in small cell lung cancer (SCLC), sponsored by Akeso, Inc. Primary endpoints: Incidence of Grade 3 or higher adverse events up to 2 years and Objective Response Rate up to 18 months. Started Mar 2021; status: completed.
02
Drugs
ivonescimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05116007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05116007.